RS BioTherapeutics Supports Federal Toxic Exposures Research Program
RS BioTherapeutics has submitted two proposals to the Toxic Exposures Research Program (TERP) in support of RSBT-001, their novel therapeutic agent for treating severe lung diseases linked to pulmonary inflammation. TERP's vision is to prevent and mitigate the effects of military-related toxic exposures aligns perfectly with our commitment to enhancing the health and well-being of those suffering from chronic lung conditions, such as COPD, which often affect military personnel. With these submissions, RS has contributed to vital research that could lead to better healthcare solutions for veterans and active service members impacted by toxic exposures.
RS BioTherapeutics Supports Federal Toxic Exposures Research Program